000132664 001__ 132664
000132664 005__ 20240229105026.0
000132664 0247_ $$2doi$$a10.1007/s00345-017-2134-1
000132664 0247_ $$2pmid$$apmid:29214353
000132664 0247_ $$2ISSN$$a0724-4983
000132664 0247_ $$2ISSN$$a1433-8726
000132664 0247_ $$2altmetric$$aaltmetric:115392557
000132664 037__ $$aDKFZ-2018-00324
000132664 041__ $$aeng
000132664 082__ $$a610
000132664 1001_ $$aNyarangi-Dix, Joanne N$$b0
000132664 245__ $$aComplete bladder neck preservation promotes long-term post-prostatectomy continence without compromising midterm oncological outcome: analysis of a randomised controlled cohort.
000132664 260__ $$aBerlin$$bSpringer$$c2018
000132664 3367_ $$2DRIVER$$aarticle
000132664 3367_ $$2DataCite$$aOutput Types/Journal article
000132664 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1525333221_1091
000132664 3367_ $$2BibTeX$$aARTICLE
000132664 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000132664 3367_ $$00$$2EndNote$$aJournal Article
000132664 520__ $$aThe only RCT available on complete bladder neck preservation (cBNP) during radical prostatectomy reported superior continence and QoL outcomes in the first 12 months after cBNP. We provide the first data on long-term urinary continence, QoL and biochemical recurrence (BCR) after complete bladder neck preservation in a randomised controlled cohort.After approval by IRB, 199 men recruited for the randomised, controlled single-blind Heidelberger cBNP Study had prostatectomy performed with (cBNP) or without (noBNP) complete bladder neck preservation. Only men with renewed consent for this follow-up were evaluated for continence, QoL outcomes and BCR by ICIQ-SF self-assessment questionnaire, Pad-use/day and PSA levels. Students-t test, Pearson´s Chi-square, Fishers exact test and multiple logistic regression analyses were applied.Mean follow-up was approx. 4 years. There were no significant differences in baseline characteristics between responders/non-responders or between study groups. We noted significantly higher continence rates (p = 0.004), less pad-use (p < 0.001), reduced frequency (p = 0.023) and amount (p = 0.009) of urine loss, and higher QoL outcomes (p = 0.012) after cBNP. A younger age positively influenced continence (OR = 0.91), but the multivariate analysis found cBNP to be the only independent predictor of continence (p = 0.008; OR = 8.1). pT stage was the only predictor for positive surgical margins (PSM; p < 0.001). There was no significant difference in pT stage (p = 0.23) or BCR (p = 0.63) between study groups and also no significant correlation between BCR and presence (p = 0.26) or localisation (p = 0.11) of PSM, nerve sparing (p = 0.70), surgeon (p = 0.41), preoperative PSA (p = 0.53) or pT stage (p = 0.17). No cancer-related death was noted.Results of this first follow-up on a prospective randomised controlled cohort demonstrate that cBNP is associated with significantly higher continence and QoL outcomes without compromising cancer control making cBNP a novel objective during radical prostatectomy.
000132664 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000132664 588__ $$aDataset connected to CrossRef, PubMed,
000132664 7001_ $$0P:(DE-He78)2ef631585610340ff425c9c31fcabd03$$aTichy, Diana$$b1$$udkfz
000132664 7001_ $$aHatiboglu, Gencay$$b2
000132664 7001_ $$aPahernik, Sascha$$b3
000132664 7001_ $$aTosev, Georgi$$b4
000132664 7001_ $$aHohenfellner, Markus$$b5
000132664 773__ $$0PERI:(DE-600)1463303-6$$a10.1007/s00345-017-2134-1$$gVol. 36, no. 3, p. 349 - 355$$n3$$p349 - 355$$tWorld journal of urology$$v36$$x1433-8726$$y2018
000132664 909CO $$ooai:inrepo02.dkfz.de:132664$$pVDB
000132664 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2ef631585610340ff425c9c31fcabd03$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000132664 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000132664 9141_ $$y2018
000132664 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000132664 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bWORLD J UROL : 2015
000132664 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000132664 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000132664 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000132664 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000132664 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000132664 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000132664 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000132664 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000132664 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000132664 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000132664 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000132664 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000132664 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x0
000132664 980__ $$ajournal
000132664 980__ $$aVDB
000132664 980__ $$aI:(DE-He78)C060-20160331
000132664 980__ $$aUNRESTRICTED